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Background: Cartilage destruction in osteoarthritis (OA) involves 
excessive degradation and increased synthesis of cartilage ma- 
trix macromolecules including type II collagen and proteoglycans. 
Cartilage biomarkers exist for the measurement of changes in 
cartilage matrix turnover. 
Aim: To determine whether there is a relationship between serum 
levels of type II collagen degradation and synthesis biomarkers 
(C2C, C1,2C and CP II) and radiological data in patients with hip 
OA and generalized OA. 
Patients and methods: 56 patients (mean age/SD: 62/11; 
BMI/SD: 27/11) with symptomatic hip OA (Lequesne index/SD: 
8.3/4.). Minimum joint space width (Min JSW) was obtained by 
computer measurement. The following serum markers were stud- 
ied using commercial kits from Ibex Diagnostics (Montreal, QC): 
type II collagen synthesis C-propeptide (CPII), cleavage by col- 
lagenase of type II (C2C) and types I and II (C1, 2C) collagens. 
The other studied variables were: age, sex, BMI, hip OA bilater- 
ality, and the number of involved joints. Patients with OA affecting 
more than 3 different joints were classified has having general- 
ized OA (GOA). 
Statistics: Multivariate analysis 
Results Unilateral hip OA without any other joint involvement was 
observed in 17 patients.Twenty two patients had bilateral hip OA 
and 24 GOA. MinJSW was 2.234-1.25 mm. 
There was a correlation between min JSW and C2C in patients 
with unilateral hip OA (R=0.50, p= 0.02). 
CPII levels were significantly lower in patients with GOA 
(99.94-50.3ng/mL versus 141.94-81.2ng/mL, p=0.04, OR= 0.18 
for CPII >120 ng/mL, [CI-95% 0.05-0.6], p<0.005). 
Conclusion: Differences in the pathogenesis of hip OA can 
be distinguished by systemic measurement of certain cartilage 
biomarkers. Generalized OA may be due to a deficiency in a 
reparative process involving type II collagen. The significant cor- 
relation between C2C and JSW in unilateral hip OA suggests that 
this marker is of value in assessing cartilage degradation in pa- 
tients with involvement of a single hip joint. 
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Purpose: Matrix metalloproteinases cleave the Type II collagen 
helix into 3/4- and 1/4-length fragments. Urinary levels of neoepi- 
topes on the larger fragment (uTIINE)have been shown to dif- 
ferentiate symptomatic OA from asymptomatic disease. This pi- 
lot study asked whether (a) baseline uTIINE levels predict radio- 
graphic and symptomatic progression of knee OA and (b) serial 
values reflect concurrent JSN. 
Methods: Subjects were 120 women with unilateral knee OA who 
completed a 30-mo RCT of structure-modification by doxycycline 
(doxy). Sixty were x-ray progressors (mean JSN 4- SD = 0.97 4- 
0.75 mm); 60 were non-progressors (-0.03 4- 0.17 mm). 
Each group contained 30 subjects who exhibited clinically signif- 
icant increases in knee pain over 30 mos and 30 who did not. 
Urine samples were collected every 6 mos for analysis of uTI- 
INE with an antibody capture assay that measured the levels of 
a 45-mer peptide resulting from collagenase cleavage of Type II 
collagen, uTIINE values were normalized for urinary creatinine 
(Cr). 
Results: Results of logistic regression analyses to predict JSN 
and knee pain are shown in Table 1. In the placebo group, uTI- 
INE was unrelated to JSN or knee pain. However, in the doxy 
group, a 1-SD increment in baseline uTIINE (68 ng/mM Cr) was 
associated with a 2-fold increase in odds of progression of JSN 
(OR 2.04, P=0.058). 
Table 1. Prediction of JSN and Knee Pain 
Outcome Placebo Group (N = 69) 
uTIINE SD = 64 ng/mM Cr 
Doxy Group (N = 51) 
uTIINE SD = 68 ng/mM Cr 
Odds Ratio* 95% CI Odds Ratio* 95% CI 
JSN 0.74 0.44 - 1.23 2.04 0.98 - 4.28 
Knee Pain 0.71 0.41 - 1.23 0.80 0.43 - 1.50 
*Change in odds of progression of JSN per 1-SD increase in the baseline 
uTIINE concentration, adjusted for baseline JSW and baseline VAS score 
for 50-ft Walk Pain. Odds ratios for prediction of knee pain were adjusted 
also for baseline BMI. 
In an analysis of JSN over discrete time intervals, mixed mod- 
els showed that both the mean and maximum of the intercurrent 
uTIINE values were associated with JSN (Table 2). 
Table 2. Concurrent Association Between uTIINE and JSN 
Intercurrent uTIINE 0-16 Month Interval 16-30 Month Interval 
SD of Parameter SD of Parameter 
uTIINE Estimate* uTIINE Estimate* 
Mean 69 0.10~: 66 0.17~:§ 
Maximum 108 0.14~: 98 0.101 
*Parameter Estimate = change in JSN, in mm, associated with a 1-SD in- 
crease in mean or maximum uTIINE concentration (ng/mM Cr) after adjust- 
ment for age, knee and JSW at the start of the interval, tP<0.05; ~:P<0.01 ; § 
A significant uTIINE by Treatment Group interaction was detected (P<0.05). 
The data shown represent he association between mean uTIINE levels and 
JSN in the placebo group only. 
Conclusion: uTIINE was not a consistent predictor of JSN or 
knee pain in subjects with knee OA. However, serial uTIINE val- 
ues reflected concurrent JSN. 
Acknowledgements: Supported by NIH AR43348, AR43370, 
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Study Aims: To evaluate whether baseline levels of interleukin 
(IL)-I, IL-6 or tumor necrosis factor (TNF)-~ are associated with 
Osteoarthrit is and Carti lage Vol. 13, Supplement  A $39  
changes in knee OA symptoms and function that occur with 
weight loss. 
Methods: Data are drawn from a larger study evaluating the ef- 
fects of weight loss in overweight and obese adults with knee OA. 
All participants met ACR criteria for knee OA, were K-L grade 2-  
3, reported pain on _> 50% of days each month in one or both 
knees and difficulty with daily activities. Pain, stiffness and func- 
tion were assessed at baseline and after 16 week weight loss 
program using WOMAC. Fasting serum samples at baseline and 
week 16 were assayed for IL-1, IL-6, and TNF-~ using multiplex 
kits (Linco Research, Inc). 
Results: Participants were (mean 4- SD) 57.0 4- 6.17 years, 
mostly white (93%), female (81.5%) and used anti-inflammatory 
medications (63%). Baseline weight was 90.6 4- 9.1 kg and 106.7 
4- 11.8 kg for women and men respectively. IL-1, IL-6 and TNF-~ 
were detectable at baseline in 48%, 28%, and 28% of the sam- 
ple, respectively. Women lost 6.14- 4.6 kg and men lost 10.4 4- 
5.5 kg. Weight loss was associated with significant (p's < 0.001) 
improvements in pain (46.2%), stiffness (49.9%) and function 
(51.9%) with no differences by gender. Higher levels of serum 
cytokines at baseline were predictive of less improvement in pain 
and function after adjustment for weight loss, age, gender and 
medications. Similar trends were found for TNF-~. Baseline cy- 
tokine concentrations were not associated with change in stiff- 
ness; cytokine levels were not associated with anti-inflammatory 
use at either time point. 
Crude and adjusted correlations between baseline serum cytokines and 
changes in pain and function in response to weight loss 
Pain Function 
Crude Model 1 Model 2 Crude Model 1 Model 2 
ILl -.420** -.474** -.550** -.298* -.552** -.614"* 
IL6 -.398* -.517"* -.503** -.230 -.407* -.413" 
TNF-a -.318 -.491"* -.474** -.145 -.334~ -.344~ 
*p<.05; **p<.01 ; ~p<.10. Model 1 : Adjusted for age, gender, baseline value. 
Model 2: Adjusted for age, gender, baseline value and weight change. 
Conclusions: Serum IL-1, IL-6 and TNF-~ concentrations are 
detectable in some overweight and obese persons with disabling 
symptomatic knee OA, and predict smaller reductions in pain and 
function to a weight loss intervention, independent of amount of 
weight lost. 
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Introduction: Tegner activity levels are frequently reported in as- 
sessing outcomes of arthroscopic knee surgery. Average Teg- 
ner scores may be misleading if the cohort of study subjects 
has widely varied activity levels prior to the index injury. Conse- 
quently, we have formulated a "Tegner Index" that calculates the 
percentage of the pre-injury activity level that is regained by the 
patient after surgical intervention. Thus, the Tegner Index normal- 
izes study results by more accurately considering each patient's 
response to therapy. The purpose of this study was to assess 
effectiveness of treatment of the knee meniscus on return to ac- 
tivity, as determined by the Tegner Index, in patients in a random- 
ized clinical trial of the Collagen Meniscus Implant (CMI). 
Methods: Patients between 18 and 60 years of age who had 
undergone one to three prior partial medial meniscectomies and 
currently continued to have clinical symptoms of meniscus pathol- 
ogy were randomized either to receive the CMI or to have an 
additional partial medial meniscectomy (control). Twenty consec- 
utive patients who met all inclusion criteria and had a minimum 
2-year follow-up had the Tegner Index calculated. There were 12 
CMI and 8 control patients. Tegner Index was calculated by sub- 
tracting the preoperative Tegner score from the 2-year score and 
dividing that difference by the difference of the pre-injury score 
less the preoperative score. The quotient is multiplied by 100 to 
obtain a percentage that represents the amount of lost activity 
that has been regained as a result of the intervention. 
Results: The average Tegner Index for the CMI patients was 
0.60; hence, two years after receiving the CMI those patients had 
regained 60% of the activity that they had lost as a result of their 
inciting injury. The control patients had an average Tegner Index 
of (negative) -0.18; thus, over the two year follow-up those pa- 
tients had continued to decrease their activity levels. This differ- 
ence was statistically significant (p=0.031) using an independent 
t-test. 
Conclusion: The Tegner Index provides the surgeon with a more 
meaningful method of assessing success of treatment based on 
the percentage of return of activity rather than looking at only the 
raw Tegner score. We found that patients who received the CMI 
for treatment of meniscus pathology had a significantly higher 
Tegner Index at two years compared to controls. 
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Aim: In this study, we defined and compared the expression of 
TG2 and FXlIIA throughout he course of spontaneous knee OA 
Hartley guinea pigs. We tested the hypothesis that TG2 serves 
as a biomarker for both early OA development in the medial tibial 
plateau and for OA progression. 
Methods: Male Hartley guinea pigs were obtained at two months 
of age and sacrificed at 2, 4, 7, 10, 12 and 18 months of age 
(n=6 in each group). One knee joint was prepared for histologi- 
cal grading and cartilage was collected from both the medial and 
lateral compartments of the other knee joint for the production of 
cDNA. Synovial fluid was collected from both knees and pooled 
for analyses. A semi-quantitative histological grading system was 
used to evaluate OA severity. ELISA was used to quantify lev- 
els found in synovial fluid of the two cartilage-associated TGs, 
TG2 and FXlIIA, in addition to cartilage oligomeric matrix protein 
(COMP). Real-time PCR was used to quantify the expression lev- 
els of TG2 and FXlIIA from both medial and lateral compartments. 
Data were analyzed by ANOVA followed by Tukey's multiple com- 
parison test, and linear regression performed. Multiple regression 
modeling was used to evaluate the association of these biomark- 
ers with histological OA severity, with p-value < 0.05 considered 
significant. 
Results: Steady-state mRNA expression of TG2 in guinea pig 
cartilage was detectable at low levels in the lateral compartment 
and increased progressively from 4 to 18 months of age in the 
tibial plateau medial compartment, the site of earliest and most 
severe OA degeneration. From 2 to 18 months of age, the mean 
cartilage TG2 m RNA expression was significantly correlated with 
